At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,743 enrolled
Drug / intervention
Rosuvastatin (Crestor) +2 moredrug
Likely dose
Rosuvastatin (Crestor) 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-week Open-label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to Compare the Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe and Simvastatin in Patients With Hypercholesterolaemia and CHD
In Brief
A Phase 3 clinical trial evaluating Rosuvastatin (Crestor), Ezetimibe, and 1 other intervention for Hypercholesterolemia and 2 related conditions. Completed, enrolled 1,743 participants across 9 sites in 9 countries.
Detailed Summary
The purpose of this study is to determine whether treatment of Rosuvastatin (CRESTOR™) or Simvastatin given as monotherapy or given in combination with Ezetimibe, will lower the Low Density Lipoprotein Cholesterol (LDL-C) in patients with Hypercholesterolaemia and Coronary Heart Disease (CHD) or a CHD Risk Equivalent, Atherosclerosis or a 10-year CHD Risk of \>20%
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Brazil, Chile, Colombia, Lithuania, Netherlands, Peru, United States, Venezuela
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedSep 2007
Primary CompletionSep 2008
TodayJul 2026
First PostedSep 6, 2007
Enrollment StartAug 1, 2007
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.8 years ago
Interventions
Rosuvastatin (Crestor)drug
10mg and 20 mg
Ezetimibedrug
10 mg
Simvastatindrug
40mg and 80 mg